-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Anatomy and physiology of translation: the academic research imperative
Gabriela Apiou-Sbirlea, Guillermo J Tearney, Reginald Birngruber, Tayyaba Hasan & Richard Rox Anderson
Special Report: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Corrigendum: Clin Invest (2012); 2(9) 603-614.
Corrigendum: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation
-
Missing data in clinical trials: a data interpretation problem with statistical solutions?
Robert Hemmings, David Wright
Interview: Clinical Investigation